Антипсихотики второго поколения в сравнении с перфеназином в терапии депрессивного синдрома у больных шизофренией

Second-generation antipsychotics (SGAs), also known as aytypicals, are not superior to the first-generation antipsychotic perphenazine in treating depression in patients with chronic schizophrenia

Although a significant improvement in depressive symptoms was found in all treatment groups over time, subanalyses found that quetiapine was significantly more effective than risperidone in the patients having a major depressive episode (MDE)

No Evidence to Support Recommendation to Use Atypicals Over First-Generation Antipsychotic